Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, has opened a new state-of-the-art facility in Granta Park, Cambridgeshire, UK.
Doubling overall capacity, the laboratories enable the team’s accelerated expansion, and the development of new, innovative products.
The new facilities accommodate recent hires to Sphere Fluidics’ commercial and leadership team, as well as preparing for further recruitment by the end of the year. The first phase of building has opened 7,000 sq ft of space and has been purpose built with state-of-the-art equipment, including a demonstration laboratory to give customers the opportunity to see the company’s single cell analysis and monoclonality assurance systems at work. The second phase, due to complete by the end of the 2023, will expand Sphere Fluidics’ footprint further to around 30,000 sq ft.
Granta Park is one of the UK’s leading life-science research parks and a world-renowned centre of excellence spanning over 120 acres of land. Sphere Fluidics’ new laboratories are in addition to offices at Babraham Research Campus, also in Cambridgeshire (UK). The company also has an established network of international distributors in Japan, France, China, Switzerland, Germany, Austria, Benelux, Australia, Scandinavia, Korea and the USA.
Dr Frank F Craig, CEO, Sphere Fluidics, commented: “We are on an exciting growth trajectory – this new site at Granta Park gives us another opportunity to attract new talent to our team, and continue our rapid expansion. With the first stage of building complete, we look forward to harnessing the space to encourage customer visits and sales and develop new products for our customers.”
For more information about Sphere Fluidics, please visit spherefluidics.com